Intrinsic activity of human immunodeficiency virus type 1 protease heterologous fusion proteins in mammalian cells.

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Intrinsic activity of human immunodeficiency virus type 1 protease heterologous fusion proteins in mammalian cells.

DNA Cell Biol. 1995 Jan;14(1):15-23. Unique Identifier : AIDSLINE MED/95134352
Arrigo SJ; Haines JK; Huffman KM; Department of Microbiology and Immunology, Medical University of; South Carolina, Charleston 29425-2230.

Abstract: We have generated various mammalian expression constructs that produce fusion proteins of human immunodeficiency virus type 1 (HIV-1) protease (PR) with the HIV-1 Nef protein. The expression of these proteins is inducible by the HIV-1 Tat protein. High-level expression of proteolytically active PR was produced from PR imbedded into Nef coding sequences, flanked by PR cleavage sites. The fusion protein was cleaved nearly to completion and did not exhibit the regulated processing that is seen with the virally encoded PR. No cytotoxic effect of PR expression was detected. The self-cleavage of PR could be inhibited by a specific inhibitor of HIV-1 PR (U75875). Elimination of the aminoterminal PR cleavage site did not have a measurable effect on cleavage of the precursor fusion protein. The cleaved fusion proteins appeared to be extremely unstable in the transfected cells. These findings demonstrate the intrinsic activity of HIV-1 PR in mammalian cells, in the context of a heterologous fusion protein.

Keywords: Animal Base Sequence Cell Line Gene Expression Regulation, Viral Gene Products, nef/*GENETICS Gene Products, tat/GENETICS Genetic Vectors/GENETICS Human HIV Protease/BIOSYNTHESIS/GENETICS/*METABOLISM HIV Protease Inhibitors/PHARMACOLOGY HIV-1/*METABOLISM Mammals Molecular Sequence Data Protein Processing, Post-Translational/DRUG EFFECTS Recombinant Fusion Proteins/BIOSYNTHESIS/METABOLISM/TOXICITY RNA, Messenger/BIOSYNTHESIS Sequence Deletion/PHYSIOLOGY Support, U.S. Gov't, P.H.S. JOURNAL ARTICLE
950530
M9551012

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .